Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

Summer's rise in COVID-19 cases led to the approval of updated versions of vaccinations targeting recent strains for the 2024 ...

Novavax (NVX-CoV2373) is a brand-name vaccine that’s prescribed to help prevent COVID-19. As with other drugs, Novavax can cause side effects, such as pain or swelling at the injection site ...

Novavax reported a net loss of $0.76/share and $84.5M in revenue, beating estimates but cutting guidance due to lower COVID-19 vaccine sales. Revenue has declined since 2022, prompting a ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected sales of its COVID-19 vaccine, ahead of handing over the rights to sell ...

Novavax shares fell after the company dropped its full-year revenue guidance with its third-quarter results. The company has cut its guidance multiple times this year, and the new range is below ...

Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year. The company now expects $650 million to $700 million in ...

The Gaithersburg biotech is preparing to turn over sales activity for its only product to its commercial partner. Novavax Inc. has made a smaller splash in the U.S. Covid-19 vaccine market than it ...

About a week later, the agency authorized an updated version of Novavax’s protein subunit vaccine for people 12 years and ...